

Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

Claim Listing

1. (Currently amended) A method for enhancing the effect of a vaccine, the method comprising administering to a patient in need thereof, a vaccine pharmaceutical composition comprising pharmaceutically acceptable particles, the particles comprising
 - (i) a biologically active agent that generates a protective immune response in an animal to which it is administered; in combination with
 - (ii) a ~~an~~ first adjuvant chemical which increases the effect of the biologically active agent, said adjuvant chemical selected from one or more being selected from the group consisting of:
 - A) polyornithine,
 - B) a water soluble vitamin or water soluble vitamin derivative,
 - C) a positively charged cationic block copolymer or a positively charged cationic surfactant,
 - D) a clathrate,
 - E) a complexing agent,
 - F) cetrimides,
 - G) an S-layer protein, or
 - H) Methyl-glucamine; and
 - (iii) a pharmaceutically acceptable carrier or diluent; subject to the following provisos
 - a) when the chemical (ii) above is selected from D) or E), the biologically active agent is an agent that generates a protective immune response in an animal to which it is administered;
 - b) when the adjuvant chemical (ii) above is selected from A) and the biologically active agent is an agent that generates a protective immune

~~response in an animal to which it is administered, the composition is for administration to a mucosal surface,~~

- ~~e) b) when the adjuvant chemical (ii) above is selected from C) and the biologically active agent is an agent that generates a protective immune response in an animal to which it is administered, the composition does not contain a polyacrylic acid, and~~
- ~~d) c) when the adjuvant chemical (ii) above is selected from G) and the biologically active agent is an agent that generates a protective immune response in an animal to which it is administered, the carrier or diluent of (iii) particle is a microsphere or liposome.~~

Claim 2 (Cancelled)

3. (Currently amended) The composition method of claim 1 wherein the adjuvant chemical acts as an immunostimulant.

4. (Currently amended) The composition method of claim 1 wherein the said adjuvant chemical is selected from one or more of;

- A) ~~the polyornithine polyornithine has having~~ a molecular weight from 5 to 150kDa;
- B) ~~the water soluble vitamin or water soluble vitamin derivative is~~ vitamin E TPGS (d-alpha tocophenyl polyethylene glycol 1000 succinate),
- C) ~~the a cationic block copolymer or the a cationic surfactant, is~~ positively charged by means of NH₂⁺ groups
- D) ~~the a complexing agent that~~ forms complexes with fatty acids, or
- E) ~~the clathrate is a cyclodextrin or a derivative thereof.~~

5. (Cancelled)

Second Amendment and Response to Office Action

Serial No. 09/937,068

Page 4 of 8

6. (Currently amended) The ~~composition~~ method of claim 5 1 wherein the ~~particle is a microsphere or liposome~~ particles are microspheres or liposomes.

7. (Currently amended) The ~~composition~~ method of claim 6 ~~which comprises a microsphere~~ wherein the particles are microspheres.

8. (Currently amended) The ~~composition~~ method of claim 7 wherein the ~~microsphere is microspheres~~ are prepared using a high molecular weight polymer.

9. (Currently amended) The ~~composition~~ method of claim 8 wherein the polymer has a molecular weight of 100kDa or more.

10. (Currently amended) The ~~composition~~ method of claim 7 wherein the microsphere comprises poly-(L-lactide).

Claim 11 (Cancelled)

12. (Currently amended) The ~~composition~~ method of claim 1 ~~which wherein the vaccine composition~~ is administered to a mucosal surface of the animal or administered parenterally to the animal.

13. (Currently amended) The ~~composition~~ method of claim 1 2 ~~which wherein the vaccine composition~~ further comprises a second adjuvant.

Claims 14-25 (Withdrawn)

26. (Currently amended) The ~~composition~~ method of claim 4 30 wherein
A) the complexing agent forms complexes with deoxycholic acid; or
B) the clathrate is dimethyl β -cyclodextrin.

27. (New) The method of claim 1 wherein the adjuvant chemical is A) polyornithine having a molecular weight from 5 to 150 kDa.

28 (New) The method of claim 1 wherein the adjuvant chemical is B) a water soluble vitamin or water soluble vitamin derivative comprising vitamin E TPGS (d-alpha tocophenyl polyethylene glycol 1000 succinate).

29. (New) The method of claim 1 wherein the adjuvant chemical is C) a cationic block copolymer or a cationic surfactant, positively charged by means of NH_2^+ groups.

30. (New) The method of claim 1 wherein the adjuvant chemical is E) a complexing agent that forms complexes with fatty acids.